Comparison of melphalan‐ And busulfan‐based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia

2020 ◽  
Vol 24 (4) ◽  
Author(s):  
Benjamin Oshrine ◽  
Lauren Adams ◽  
Anh Thy H. Nguyen ◽  
Ernest Amankwah ◽  
David Shyr ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Allogeneic Transplantation ◽  
Myeloablative Conditioning ◽  
Acute Myeloid

How I treat acute myeloid leukemia

Blood ◽  
2010 ◽  
Vol 116 (17) ◽  
pp. 3147-3156 ◽  
Author(s):  
Jacob M. Rowe ◽  
Martin S. Tallman
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Allogeneic Transplantation ◽  
Malignant Cell ◽  
Current Approach ◽  
Molecular Abnormalities ◽  
The Past ◽  
Survival Pathways ◽  
Large Populations ◽  
Acute Myeloid

AbstractMore than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML). Despite considerable progress during the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of older adults still die of their disease. The reported median age has increased over the past few decades, mostly because of a greater willingness of physicians to diagnose and treat older patients, and now is 72 years. The greatest challenge is in this age group. However, much improvement in therapy is needed for all adults with AML. Recent advances in allogeneic transplantation, a better understanding of prognostic factors, and development of targeted agents have only modestly improved overall outcome when large populations of patients are considered. Although an explosion in knowledge about the molecular pathogenesis of AML has outpaced treatment advances, such insights hold promise for the development of new therapies directed at specific molecular abnormalities that perturb malignant cell survival pathways. The current approach in 2010 to the management of this disease is presented through a discussion of illustrative cases.

scholarly journals Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation

HemaSphere ◽  
2020 ◽  
Vol 4 (1) ◽  
pp. e326
Author(s):  
Madlen Jentzsch ◽  
Juliane Grimm ◽  
Marius Bill ◽  
Karoline Goldmann ◽  
Julia Schulz ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Allogeneic Transplantation ◽  
Acute Myeloid

Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia – improved outcomes with similar toxicity

2018 ◽  
Vol 60 (3) ◽  
pp. 726-733 ◽  
Author(s):  
Vipul Sheth ◽  
Boaz Nachmias ◽  
Sigal Grisariu ◽  
Batia Avni ◽  
Reuven Or ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Myeloablative Conditioning ◽  
Improved Outcomes ◽  
Acute Myeloid

scholarly journals Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India

2017 ◽  
Vol 3 (6) ◽  
pp. 773-781 ◽  
Author(s):  
Abhijeet Ganapule ◽  
Sandeep Nemani ◽  
Anu Korula ◽  
Kavitha M. Lakshmi ◽  
Aby Abraham ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
Cost Effective ◽  
Effective Strategy ◽  
Event Free Survival ◽  
Myeloablative Conditioning ◽  
Free Survival ◽  
Acute Myeloid

Purpose There are limited data from developing countries on the role and cost-effectiveness of allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML). Patients and Methods We undertook a retrospective descriptive study of all patients with AML who underwent allo-SCT from 1994 to 2013 at our center to evaluate the clinical outcomes and cost-effectiveness of this therapeutic modality. Results Two hundred fifty-four consecutive patients, median age 34 years, who underwent allo-SCT at our center were included in this study. There were 161 males (63.4%). The 5-year overall survival (OS) and event-free survival for the entire cohort was 40.1 ± 3.5% and 38.7 ± 3.4%, respectively. The 5-year OS for patients in first (CR1), second, and third complete remission and with disease/refractory AML was 53.1 ± 5.2%, 48.2 ± 8.3%, 31.2 ± 17.8%, and 16.0 ± 4.4%, respectively ( P < .001). From 2007, reduced intensity conditioning (RIC) with fludarabine and melphalan (Flu/Mel) was used in a majority of patients in CR1 (n = 67). Clinical outcomes were compared with historical conventional myeloablative conditioning regimens (n = 38). Use of Flu/Mel was associated with lower treatment-related mortality at 1 year, higher incidence of chronic graft-versus-host-disease, and comparable relapse rates. The 5-year OS and event-free survival for Flu/Mel and myeloablative conditioning group was 67.2 ± 6.6% versus 38.1 ± 8.1% ( P = .003) and 63.8 ± 6.4% versus 32.3 ± 7.9% ( P = .002), respectively. Preliminary cost analysis suggests that in our medical cost payment system, RIC allo-SCT in CR1 was likely the most cost-effective strategy in the management of AML. Conclusion In a resource-constrained environment, Flu/Mel RIC allo-SCT for AML CR1 is likely the most efficacious and cost-effective approach in a subset of newly diagnosed young adult patients.

scholarly journals Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission

Cancer ◽  
2017 ◽  
Vol 123 (11) ◽  
pp. 2025-2034 ◽  
Author(s):  
Daniel J. Weisdorf ◽  
Heather R. Millard ◽  
Mary M. Horowitz ◽  
Parvinder S. Hyare ◽  
Richard Champlin ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Complete Remission ◽  
Myeloid Leukemia ◽  
Allogeneic Transplantation ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document